Lattice Biologics Ltd V.LBL.H

Alternate Symbol(s): LBLTF

Healthcare Biotechnology

Lattice Biologics Ltd. is engaged in the business of developing, manufacturing and marketing biologics products to domestic and international markets. The Company’s products are used in a variety of applications including enhancing bone regeneration in dental, spine, and general orthopedic indications. Its acellular dermal matrix is used for dental flaps which is used to close defects post-implantation. The Company’s stem cell-based technology AmnioBoost, is an amniotic fluid concentrate, which can be used to accelerate and enhance bone regeneration for dental post implantation. In addition, its products complimentary to the dental allograft market are amniotic membrane, Demineralized bone matrix (DBM) putty, acellular dermal matrix and cancellous DBM sponges.

TSXV:LBL.H - Post by User

Lattice Biologics Ltd > March 17 NR

<< Previous

Bullboard Posts

Next >>

Post by Magnum2on May 04, 2020 11:52am

145 Views

Post# 30983749

March 17 NR

In the initial stage of investigation, the clinicians will compare participant outcomes on day seven in both groups to assess if AmnioBoost treatment has produced any clinical benefit.
The study will be halted if there is no evidence of a treatment difference between AmnioBoost and placebo.

So if we had bad news/no evidence of a treatment difference, we would have heard by now....correct???

<< Previous

Bullboard Posts

Next >>

Cross border trading in Canada and Australia